2024    2023    2022    2021    2020    2019    2018    2017    2016   

2024

Articles

71 - 

Extending the code in the open-source saemix package to fit joint models of longitudinal and time-to-event data

Alexandra Lavalley‐morelle, France Mentré, Emmanuelle Comets, Jimmy Mullaert

Computer Methods and Programs in Biomedicine, 2024, Computer Methods and Programs in Biomedicine, 247, pp.108095.

DOI : https://doi.org/10.1016/j.cmpb.2024.108095

Pubmed : 38422892

 

72 - 

How can the environmental sustainability of healthcare products be taken into account throughout their life cycle?

Bruno Laviolle, Pierre-Frédéric Degon, Cécile Gillet Giraud, Dominique Thiveaud, Philippe Lechat et al.

Therapies, 2024, 79 (1), pp.61-74.

DOI : https://doi.org/10.1016/j.therap.2023.12.001

Pubmed : 38102030

 

73 - 

Le groupe FRANCOGYN : bilan et avenir FRANCOGYN group: A brief history

Vincent Lavoué, Emilie Raimond, Marcos Ballester, Xavier Carcopino, Henri Azaïs et al.

Le groupe FRANCOGYN : bilan et avenir. Gynecologie, Obstetrique, Fertilite and Senologie, 2024, 52 (1), pp.51-54.

DOI : https://doi.org/10.1016/j.gofs.2023.10.005

Pubmed : 37839793

 

74 - 

Clinical and histological features of histiocytoid Sweet syndrome associated with VEXAS syndrome

Hortense Lecoeuvre, Franҫois Le Gall, Cécile Le Naoures Mear, Marie Dominique Vignon-Pennamen, Claire Lamaison et al.

Clinical and Experimental Dermatology, 2024, Clinical and Experimental Dermatology,

DOI : https://doi.org/10.1093/ced/llae015

Pubmed : 38366665

 

75 - 

Isotrétinoïne : quelles actualités en dermatologie ? Conclusions du séminaire Centre de preuves en dermatologie et groupe DEFI de la SFD Isotretinoin: What's new in dermatology? Conclusions from the workshop organized by the Centre of Evidence of the French Society of Dermatology and the French Facial Dermatosis Group (groupe DEFI)

S Leducq, Florence Poizeau, G. Chaby, J. Tannous, F. Ballanger-Desolneux et al.

Isotrétinoïne : quelles actualités en dermatologie ? Conclusions du séminaire Centre de preuves en dermatologie et groupe DEFI de la SFD. Annales de Dermatologie et de Vénéréologie - FMC, 2024, Annales de Dermatologie et de Vénéréologie - F-C, 4 (2), pp.144-154.

DOI : https://doi.org/10.1016/j.fander.2023.06.005

 

76 - 

Therapeutic drug monitoring and virological response at week 48 in a cohort of HIV-1 infected-patients switching to dolutegravir/rilpivirine dual maintenance therapy (ANRS-MIE-BIRIDER Study)

Florian Lemaitre, Jennifer Lagoutte-Renosi, Marie-Claude Gagnieu, François Parant, Nicolas Venisse et al.

British Journal of Clinical Pharmacology, 2024, 90 (1), pp.264-273.

DOI : https://doi.org/10.1111/bcp.15890

Pubmed : 37602480

 

77 - 

Harmonized quality assurance/quality control provisions to assess completeness and robustness of MS1 data preprocessing for LC-HRMS-based suspect screening and non-targeted analysis

Sarah Lennon, Jade Chaker, Elliott Price, Juliane Hollender, Carolin Huber et al.

Trends in Analytical Chemistry, 2024, 174, pp.117674.

DOI : https://doi.org/10.1016/j.trac.2024.117674

 

78 - 

Systemic sclerosis, silica exposure and cellular therapies: The sand in the gears?

A Lescoat, D Rimar, D Farge

La Revue de Médecine Interne, 2024, La Revue de Medecine Interne,

DOI : https://doi.org/10.1016/j.revmed.2024.02.003

Pubmed : 38395716

 

79 - 

Pre-scleroderma and new opportunities for preventive medicine – Authors’ reply

Alain Lescoat, Dinesh Khanna, Masataka Kuwana, Yannick Allanore, Marco Matucci-Cerinic et al.

The Lancet Rheumatology, 2024, 6 (4), pp.e201.

DOI : https://doi.org/10.1016/s2665-9913(24)00058-4

 

80 - 

Comité de surveillance indépendant dans les essais cliniques : de la justification scientifique à l’organisation

Clara Locher, Silvy Laporte, Peggy Derambure, Olivier Chassany, Cécile Girault et al.

Therapies, 2024, 79 (1), pp.99-110.

DOI : https://doi.org/10.1016/j.therap.2023.10.013

Pubmed : 37985309